Joseph P. Lyssikatos - 08 Jan 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
08 Jan 2026
Net transactions value
-$3,476,014
Form type
4
Filing time
12 Jan 2026, 17:12:59 UTC
Previous filing
23 Dec 2025
Next filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 12 Jan 2026 0001967150

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale $150,962 -7,500 -0.84% $20.13 890,188 08 Jan 2026 See footnote F1, F2, F3
transaction ELVN Common Stock Sale $842,474 -33,802 -3.8% $24.92 856,386 08 Jan 2026 See footnote F1, F3, F4
transaction ELVN Common Stock Sale $1,025,863 -41,198 -4.8% $24.90 815,188 09 Jan 2026 See footnote F1, F3, F5
transaction ELVN Common Stock Sale $1,456,715 -50,000 -6.1% $29.13 765,188 09 Jan 2026 See footnote F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F4 This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.